• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

MVP says it expects to respond to clinical hold on Penthrox by early 2020

Penthrox methoxyflurane inhaler maker Medical Developments International said that it recently met with the FDA regarding the agency’s August 2018 clinical hold letter on Penthrox, and the company now has a path forward to resolve the issues. Penthrox is already approved in Australia, Canada, and the majority of Europe.

According to MVP, the FDA has dropped a request for an animal study to predict idiosyncratic hepatoxicity. MVP had initially proposed excluding healthy volunteers from the study if they had previously experienced hepatoxicity from methyoxyflurane or halothane, and the agency had asked for changes to the exclusion criteria. The company will perform a study in animals that “replicates the human dosing regimen” for the inhaler, which is expected to take approximately 6 months.

MVP CEO John Sharman commented, “We had a good discussion with the FDA and we are clear as to what is required. Of particular importance is the willingness of the FDA to consider the recent safety data generated in Europe, and in particular the United Kingdom’s Post Authorisation Safety Study. We are confident this data will prove the safety of Penthrox to the satisfaction of the FDA and expect to submit our full response to the IND clinical hold during early 2020.”

Read the MVP press release.

Share

published on July 19, 2019

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    © 2025 OINDPnews